Natera, Inc. (45E)
XETRA 
Summary
45E Chart
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer
NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference
Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women's health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrowing losses while maintaining elevated investment levels.
Natera, Inc. (45E) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Natera, Inc. ever had a stock split?
Natera, Inc. Profile
| Professional Services Industry | Industrials Sector | Steven Leonard Chapman CEO | XETRA Exchange | US6323071042 ISIN |
| US Country | 6,138 Employees | - Last Dividend | - Last Split | 2 Jul 2015 IPO Date |
Overview
Natera, Inc. is a diagnostics company that focuses on developing and commercializing a range of molecular testing services on a global scale. The company's comprehensive portfolio includes tests for prenatal screening, carrier screening, genetic conditions, cancer profiling, and organ transplant rejection, among others. Founded in 2003, Natera is based in Austin, Texas and operates worldwide, selling its products through a direct sales force as well as a network of laboratory and distribution partners. The company also engages in strategic partnerships, such as with BGI Genomics Co., Ltd. and Foundation Medicine, Inc., to further expand its offerings in next-generation sequencing (NGS)-based genetic testing assays and personalized cancer monitoring tests.
Products and Services
- Panorama: A non-invasive prenatal test for detecting chromosomal abnormalities in fetuses, including in twin pregnancies.
- Horizon: A carrier screening test designed for individuals and couples to identify if they carry genetic variations that can lead to certain genetic conditions.
- Vistara: A single-gene non-invasive prenatal test that screens for 25 single-gene disorders responsible for severe skeletal, cardiac, and neurological conditions.
- Spectrum: Preimplantation genetic tests for couples undergoing in vitro fertilization (IVF) to help ensure the health of their future child.
- Anora: A test that analyzes miscarriage tissue to determine the genetic cause of a miscarriage in women.
- Empower: A hereditary cancer screening test to assess the risk of developing cancer based on genetic predisposition.
- Non-Invasive Prenatal Paternity: A product that allows couples to establish paternity for their child before birth using non-invasive methods.
- Signatera: A circulating tumor DNA (ctDNA) blood test used for assessing molecular residual disease and monitoring for cancer recurrence in previously diagnosed patients.
- Altera: A comprehensive genomic profiling test performed on tissue samples to guide cancer treatment decisions.
- Prospera: A test that assesses active rejection in patients who have undergone kidney, heart, or lung transplants to ensure successful organ acceptance.
- Renasight: A kidney gene panel test designed to inform patients of their risks of developing various kidney diseases.
- Constellation: A cloud-based software product that allows laboratory customers to access Natera's algorithms and bioinformatics through the cloud for test validation and launch.
